In this cohort study of 97 156 adults with type 2 diabetes, use of GLP-1 RAs was associated with significantly lower risks of major adverse cardiovascular events, cardiovascular death, and hospitalization for heart failure among patients with BMI of 25 or greater. Here, GLP1R is linked to heart failure.